GSA Capital Partners LLP Has $54,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

GSA Capital Partners LLP decreased its holdings in shares of Immunic, Inc. (NASDAQ:IMUX) by 71.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,766 shares of the company’s stock after selling 83,999 shares during the period. GSA Capital Partners LLP’s holdings in Immunic were worth $54,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in IMUX. Virtu Financial LLC acquired a new stake in shares of Immunic during the 1st quarter worth approximately $25,000. Ikarian Capital LLC grew its stake in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the period. Vanguard Group Inc. increased its position in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Immunic in the first quarter valued at approximately $9,266,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Insider Activity at Immunic

In other news, Director Richard Alan Rudick bought 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IMUX has been the topic of a number of research reports. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright began coverage on shares of Immunic in a research report on Monday. They set a “buy” rating and a $10.00 target price for the company. B. Riley started coverage on shares of Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target on the stock. Leerink Partners reissued an “outperform” rating and set a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $11.80.

Immunic Trading Up 7.3 %

IMUX stock opened at $1.18 on Tuesday. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11. The stock has a market cap of $106.29 million, a P/E ratio of -0.96 and a beta of 1.88. The stock’s fifty day simple moving average is $1.39 and its two-hundred day simple moving average is $1.34.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.